LNP023 + Eculizumab + Ravulizumab
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Trial Timeline
Jan 25, 2021 → Mar 6, 2023
NCT ID
NCT04558918About LNP023 + Eculizumab + Ravulizumab
LNP023 + Eculizumab + Ravulizumab is a phase 3 stage product being developed by Novartis for Paroxysmal Nocturnal Hemoglobinuria (PNH). The current trial status is completed. This product is registered under clinical trial identifier NCT04558918. Target conditions include Paroxysmal Nocturnal Hemoglobinuria (PNH).
What happened to similar drugs?
0 of 20 similar drugs in Paroxysmal Nocturnal Hemoglobinuria (PNH) were approved
Approved (0) Terminated (4) Active (16)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04558918 | Phase 3 | Completed |
Competing Products
20 competing products in Paroxysmal Nocturnal Hemoglobinuria (PNH)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 44 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 36 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 44 |
| Ravulizumab | AstraZeneca | Pre-clinical | 30 |
| Eculizumab | AstraZeneca | Phase 3 | 40 |
| Danicopan | AstraZeneca | Phase 3 | 47 |
| LNP023 | Novartis | Pre-clinical | 33 |
| Iptacopan (LNP023) | Novartis | Phase 3 | 40 |
| iptacopan | Novartis | Phase 2 | 35 |
| LNP023 | Novartis | Phase 2 | 35 |
| Iptacopan | Novartis | Pre-clinical | 30 |
| Iptacopan | Novartis | Phase 3 | 40 |
| LNP023 | Novartis | Phase 3 | 47 |
| LFG316 + LNP023 | Novartis | Phase 2 | 35 |
| Iptacopan | Novartis | Phase 3 | 44 |
| Crovalimab | Roche | Phase 3 | 44 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 40 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 33 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 27 |
| Humanized anti-Factor Bb monoclonal antibody + Placebo | Sanofi | Phase 1 | 29 |